Aitken Campbell Kynoch, Tracy Samantha Lilly, Revill Peter, Bharadwaj Mandvi, Bowden David Scott, Winter Rebecca Jane, Hellard Margaret Elena
Macfarlane Burnet Institute for Medical Research and Public Health, 85 Commercial Rd, Melbourne, Victoria 3004, Australia.
J Clin Virol. 2008 Apr;41(4):293-6. doi: 10.1016/j.jcv.2007.12.007. Epub 2008 Feb 1.
The hepatitis C virus (HCV) causes significant morbidity and mortality worldwide, and is highly prevalent among injecting drug users (IDUs). Whether initial HCV infection and clearance provides protection from reinfection has not been established, but is an important question for vaccine development.
To elucidate an unusual history of HCV infection and clearance in an IDU.
The subject was interviewed and gave blood samples at approximately three-month intervals; all samples were tested for anti-HCV and HCV RNA, genotyped if RNA detected, and checked for mixed genotypes; phylogenetic analysis performed on the subject's and injecting partners' core HCV sequences.
We observed consecutive infections with HCV genotypes 3a, 1a and 6l, and intervening clearances, in a young IDU over 449 days. Genotypes 1a and 6l were probably acquired from the subject's injecting partners, who had genetically related infections.
This case illustrates (1) the ease with which IDUs can acquire HCV, (2) that prior HCV infection does not protect against reinfection with heterologous strains, and (3) that IDUs can clear consecutive HCV infections. Our subject's history of HCV infection and clearance offers hope for vaccine development, yet demonstrates that HCV vaccines must have cross-genotypic effectiveness.
丙型肝炎病毒(HCV)在全球范围内导致了严重的发病率和死亡率,在注射吸毒者(IDU)中高度流行。初始HCV感染和清除是否能预防再次感染尚未明确,但这是疫苗研发中的一个重要问题。
阐明一名注射吸毒者不寻常的HCV感染和清除病史。
对该研究对象进行访谈,并大约每三个月采集一次血样;所有样本均检测抗-HCV和HCV RNA,若检测到RNA则进行基因分型,并检查是否存在混合基因型;对该研究对象及其注射伙伴的HCV核心序列进行系统发育分析。
我们观察到一名年轻的注射吸毒者在449天内先后感染了HCV 3a型、1a型和6l型,并出现了中间的清除情况。1a型和6l型可能是从该研究对象具有基因相关感染的注射伙伴那里获得的。
该病例表明(1)注射吸毒者很容易感染HCV,(2)先前的HCV感染不能预防异源毒株的再次感染,(3)注射吸毒者可以清除连续的HCV感染。我们研究对象的HCV感染和清除病史为疫苗研发带来了希望,但也表明HCV疫苗必须具有跨基因型的有效性。